Adolescent cannabis use is associated with an increased risk for new psychiatric disorders during key developmental stages.

FDA expands Juxtapid approval for pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia to reduce plasma LDL-C levels.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Telemedicine for certain conditions may be cheaper and lead to fewer short-term follow-up visits, reducing the overall cost of care burden.

The HHS pushes for additional nutrition training in medical schools, some experts agree but approach the implementation with skepticism.

Traumatic brain injury is associated with increased all-cause mortality, an association primarily driven by dementia-related death.

Veterans with a history of Grade III mTBI show significant changes in brain waste-clearance pathways, suggesting long-term glymphatic system impact.

GLP-1 RAs are prescribed to about 20% of potentially eligible adolescents, with increasing odds based on several individual factors.

Current smoking status may be linked to lower risk for Parkinson disease, but health experts aren't sure what drives this association.

The growing burden of ALS in the US highlights the need for earlier diagnosis, multidisciplinary care, and expanded access to emerging therapies.

A new drug may help treat and eventually eliminate sleeping sickness by improving adherence and accessibility to treatment.

New genetic data shows no meaningful overlap between vitamin B12 status determinants and Parkinson disease outcomes in clinical cohorts.